GelStat Corp.

GSAC

US3685331056

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:12:22 05/06/2024 pm IST			5-day change	1st Jan Change
0.0004 ^USD	0.00%		0.00%	+33.33%

07/05	GelStat Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GelStat Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

GelStat Corporation Names Roger Cady as Chief Medical Advisor

April 01, 2014 at 04:33 pm IST

GelStat Corporation announced that Roger Cady, M.D. has agreed to become the company's Chief Medical Advisor and to assist the company with developing several of its new migraine products.

Latest news about GelStat Corp.

GelStat Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/05	CI
GelStat Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
GelStat Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/23/13	CI
GelStat Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
GelStat Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/22/04	CI
GelStat Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	03/22/03	CI
GelStat Corporation Auditor Raises 'Going Concern' Doubt	02/22/02	CI
GelStat Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	24/21/24	CI
GelStat Corp. Auditor Raises 'Going Concern' Doubt	29/21/29	CI
GelStat Corporation Announces Management Changes	17/15/17	CI
GelStat Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for 2015	16/15/16	CI
GelStat Corp. Announces Consolidated Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for 2015	03/15/03	CI
GelStat Corporation Reports Consolidated Earnings Results for the Third Quarter Ended September 30, 2014; Provides Revenue Guidance for the Fourth Quarter Ending December 31, 2014	17/14/17	CI
GelStat Corporation Reports Consolidated Revenue Results for the Third Quarter Ended September 30, 2014; Revises Revenue Guidance for the Fourth Quarter Ending December 31, 2014	27/14/27	CI
GelStat Corporation Signs Distribution Agreement with Next Distributors, LLC	29/14/29	CI
GelStat Corp. Reports Revenue Results for the Second Quarter Ended June 30, 2014; Provides Revenue Guidance for the Third and Fourth Quarters of 2014	19/14/19	CI
GelStat Corp. completed the acquisition of Mastix Medica LLC.	07/14/07	CI
GelStat Corporation Signs Distribution Agreement with Windmill Health Products for the Distribution of 'Chews 2 Lose' Appetite Suppressant Gum	24/14/24	CI
GelStat Corp. signed a definitive agreement to acquire Mastix Medica LLC for $1.4 million.	05/14/05	CI
GelStat Corporation Launches Chews 2 Lose, its New Appetite Suppressant Gum	29/14/29	CI
GelStat Corporation Names Roger Cady as Chief Medical Advisor	01/14/01	CI
GelStat Corporation Receives Initial Purchase Order from Windmill Health Products	27/14/27	CI
GelStat Corporation Announces Executive Changes	23/13/23	CI
GelStat Corp. completed the acquisition of CBD LIFE SCIENCES, INC. from Larry Gershman.	23/13/23	CI
GelStat Corp. entered into a letter of intent to acquire CBD LIFE SCIENCES, INC. from Larry Gershman.	10/13/10	CI

GelStat Corporation is engaged in research, development, marketing and branding of advanced technology operations. The Company's subsidiary, GSAC Engineering Corporation, is engaged in the development of technologies for clean energy and industrial security. The Company has acquired the intellectual property of Duos Technologies Group, Inc.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GELSTAT CORP.	+33.33%	1.2M
ELI LILLY AND COMPANY	+42.48%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-6.25%	356B
MERCK & CO., INC.	+18.79%	326B
ABBVIE INC.	+6.23%	286B
ASTRAZENECA PLC	+18.08%	246B
ROCHE HOLDING AG	-3.44%	213B
NOVARTIS AG	+11.35%	213B
PFIZER, INC.	+2.45%	167B